Literature DB >> 21856257

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Pierre-Luc Mercier1, Magdalena Bachvarova, Marie Plante, Jean Gregoire, Marie-Claude Renaud, Karim Ghani, Bernard Têtu, Isabelle Bairati, Dimcho Bachvarov.   

Abstract

In attempt to discover novel aberrantly hypermethylated genes with putative tumor suppressor function in epithelial ovarian cancer (EOC), we applied expression profiling following pharmacologic inhibition of DNA methylation in EOC cell lines. Among the genes identified, one of particular interest was DOK1, or downstream of tyrosine kinase 1, previously recognized as a candidate tumor suppressor gene (TSG) for leukemia and other human malignancies. Using bisulfite sequencing, we determined that a 5'-non-coding DNA region (located at nt -1158 to -850, upstream of the DOK1 translation start codon) was extensively hypermethylated in primary serous EOC tumors compared with normal ovarian specimens; however, this hypermethylation was not associated with DOK1 suppression. On the contrary, DOK1 was found to be strongly overexpressed in serous EOC tumors as compared to normal tissue and importantly, DOK1 overexpression significantly correlated with improved progression-free survival (PFS) values of serous EOC patients. Ectopic modulation of DOK1 expression in EOC cells and consecutive functional analyses pointed toward association of DOK1 expression with increased EOC cell migration and proliferation, and better sensitivity to cisplatin treatment. Gene expression profiling and consecutive network and pathway analyses were also confirmative for DOK1 association with EOC cell migration and proliferation. These analyses were also indicative for DOK1 protective role in EOC tumorigenesis, linked to DOK1-mediated induction of some tumor suppressor factors and its suppression of pro-metastasis genes. Taken together, our findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude that DOK1 represents a true TSG in EOC. Further studies are needed to more completely elucidate the functional implications of DOK1 and other members of the DOK gene family in ovarian tumorigenesis.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856257      PMCID: PMC5528302          DOI: 10.1016/j.molonc.2011.07.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  80 in total

1.  The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells.

Authors:  I Tamir; J C Stolpa; C D Helgason; K Nakamura; P Bruhns; M Daeron; J C Cambier
Journal:  Immunity       Date:  2000-03       Impact factor: 31.745

2.  Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma.

Authors:  Bei-Fang Ning; Jin Ding; Chuan Yin; Wei Zhong; Kun Wu; Xin Zeng; Wen Yang; Yue-Xiang Chen; Jun-Ping Zhang; Xin Zhang; Hong-Yang Wang; Wei-Fen Xie
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis.

Authors:  Q Shi; Q Xiong; B Wang; X Le; N A Khan; K Xie
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

4.  Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok.

Authors:  Y Yamanashi; D Baltimore
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

5.  Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak.

Authors:  Z Master; N Jones; J Tran; J Jones; R S Kerbel; D J Dumont
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 6.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.

Authors:  S B Baylin; M Esteller; M R Rountree; K E Bachman; K Schuebel; J G Herman
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

Review 7.  Identifying DNA methylation biomarkers of cancer drug response.

Authors:  Sabine Maier; Christina Dahlstroem; Carolina Haefliger; Achim Plum; Christian Piepenbrock
Journal:  Am J Pharmacogenomics       Date:  2005

8.  Role of Dok1 in cell signaling mediated by RET tyrosine kinase.

Authors:  Hideki Murakami; Yumiko Yamamura; Yohei Shimono; Kumi Kawai; Kei Kurokawa; Masahide Takahashi
Journal:  J Biol Chem       Date:  2002-06-26       Impact factor: 5.157

Review 9.  Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.

Authors:  M Esteller
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.

Authors:  Sylvain L'Espérance; Magdalena Bachvarova; Bernard Tetu; Anne-Marie Mes-Masson; Dimcho Bachvarov
Journal:  BMC Genomics       Date:  2008-02-26       Impact factor: 3.969

View more
  16 in total

1.  Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.

Authors:  Maha Siouda; Jiping Yue; Ruchi Shukla; Sophie Guillermier; Zdenko Herceg; Marion Creveaux; Rosita Accardi; Massimo Tommasino; Bakary S Sylla
Journal:  Mol Cell Biol       Date:  2012-10-01       Impact factor: 4.272

2.  Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Authors:  Pierre-Luc Mercier; Magdalena Bachvarova; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Karim Ghani; Bernard Têtu; Isabelle Bairati; Dimcho Bachvarov
Journal:  Mol Oncol       Date:  2011-07-26       Impact factor: 6.603

3.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

4.  Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice.

Authors:  Yi Shen; Jun Ma; Ruilan Yan; Hongyan Ling; Xiaoning Li; Wancai Yang; John Gao; Chenfei Huang; Yiwen Bu; Yu Cao; Yingchun He; Laxiang Wan; Xuyu Zu; Jianghua Liu; Mei Chris Huang; William F Stenson; Duan-Fang Liao; Deliang Cao
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

5.  Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells.

Authors:  Zhi-Qiang Wang; Mamadou Keita; Magdalena Bachvarova; Stephane Gobeil; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

6.  Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.

Authors:  Zhi-Qiang Wang; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Dimcho Bachvarov
Journal:  Oncotarget       Date:  2014-01-30

7.  Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.

Authors:  Melchiorre Cervello; Dimcho Bachvarov; Nadia Lampiasi; Antonella Cusimano; Antonina Azzolina; James A McCubrey; Giuseppe Montalto
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

8.  BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.

Authors:  Sayem Miah; Raghuveera Kumar Goel; Chenlu Dai; Natasha Kalra; Erika Beaton-Brown; Edward T Bagu; Keith Bonham; Kiven E Lukong
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

9.  EgoNet: identification of human disease ego-network modules.

Authors:  Rendong Yang; Yun Bai; Zhaohui Qin; Tianwei Yu
Journal:  BMC Genomics       Date:  2014-04-28       Impact factor: 3.969

10.  E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.

Authors:  Jibin Li; Xinling Wang; Yanshang Zhang; Yan Zhang
Journal:  Exp Ther Med       Date:  2016-06-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.